HEALTHCARE (NY:XLV)

The healthcare sector outperformed the rest of the market over the past week.

Topics ETFs

Healthcare Stocks Are on Fire -- Don't Miss These Opportunities ↗

May 22, 2026

Defense, healthcare, and financial stocks may outperform ahead of midterm elections as investors position for policy shifts

Topics Artificial Intelligence ETFs Economy

These Stocks Could Be the Biggest Winners of the 2026 Midterms ↗

May 18, 2026

Topics Economy Stocks

BSX Stock Tumbles Pre-Market On Softer 2026 Sales Growth Forecast ↗

February 04, 2026

Healthcare stocks have been laggards for a while now. The current economic slowdown and structural tailwinds make it much more attractive now.

1 No-Brainer Healthcare Vanguard ETF to Buy Right Now for Less Than $1,000 ↗

April 13, 2026

The long-standing "gender gap" in the American workforce has effectively closed. According to the Bureau of Labor Statistics (BLS) report released for the first quarter of 2026, the participation rate...

Topics Artificial Intelligence ETFs Economy

The Great Balancing Act: U.S. Gender Labor Gap Closes for the First Time in History

March 26, 2026

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

What Q1 Earnings Could Mean for the S&P 500 Uptrend ↗

March 24, 2026

AbbVie has strong financials, a great dividend, and its stock trades at a modest valuation.

Topics Stocks

Why AbbVie Stock Looks Like a Dirt Cheap Buy Right Now ↗

March 23, 2026

The biotech sector has found its new North Star in 2026. As of mid-March, Moderna Inc. (NASDAQ: MRNA) has shocked Wall Street with a staggering 83% year-to-date gain, catapulting it to the upper...

Topics ETFs Intellectual Property

The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery

March 16, 2026

Via MarketMinute

Topics Artificial Intelligence Initial Public Offering Stocks

The S&P 500's 3 Best-Performing Stocks so far in 2026 ↗

March 16, 2026

HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism ↗

Topics Stocks

March 05, 2026

In the study, participants receiving a 20-milligram dose of HLP004 alongside standard-of-care treatment experienced an average drop of roughly 10.4 points on the Hamilton Anxiety Rating Scale after six...

As of late February 2026, the financial narrative of the past two years has been dominated by a singular force in the healthcare sector: Eli Lilly & Company (NYSE: LLY). Once considered a traditional...

The Lilly Era: How Eli Lilly Transformed into a Trillion-Dollar Healthcare Titan

February 27, 2026

Via MarketMinute

Topics Artificial Intelligence ETFs

Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue ↗

February 26, 2026

The company generated $147 million in revenue during Q4, a 67% year-on-year (YoY) increase. Earnings per share (EPS) for the quarter were $0.11.

PRCT Stock Tumbles Pre-Market: BofA Questions Earnings Visibility, Cuts Target To $20 ↗

Topics Artificial Intelligence

February 26, 2026

Bank of America reduced its rating on PROCEPT BioRobotics to ‘Underperform’ from ‘Neutral’.

CASI stated the Nasdaq determined that the company had failed to satisfy the continued listing conditions to remain listed on the Nasdaq Stock Market.

Topics Artificial Intelligence

Why Did CASI Stock Plummet 64% Today To Hit An All-Time Low? ↗

February 25, 2026

The company’s board approved a 1-for-30 reverse stock split, effective on February 26.

Why Did IXHL Stock Tank Over 32% Today? ↗

February 25, 2026

The FDA has granted Breakthrough Therapy Designation to Larimar’s frataxin protein replacement therapy, nomlabofusp.

Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? ↗

February 24, 2026

VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership ↗

February 24, 2026

Raymond James analyst Sean McCutcheon upgraded the stock to ‘Strong Buy’ from ‘Outperform’ and lifted his price target to $19 from $12.

The company announced encouraging early results from a pilot study evaluating its tumor-infiltrating lymphocyte therapy, lifileucel and reported strong fourth-quarter earnings.

Why Did IOVA Stock Gain Pre-Market Today? ↗

February 24, 2026

Why Is GRAL Stock Down Today? Analysts Lower Targets After UK Trial Setback But Call Selloff Overdone ↗

February 20, 2026

Baird analyst Catherine Ramsey Schulte slashed the price target on Grail to $82 from $113 while reiterating an ‘Outperform’ rating.

Intensity Therapeutics announced a 1-for-25 reverse stock split, consolidating every 25 existing shares into a single new share.

Why Did INTS Stock Plummet 30% Pre-Market Today? ↗

February 13, 2026

Immunic announced a private placement of up to $400 million to support its clinical studies and other operational needs.

Why Did IMUX Stock Surge 33% Pre-Market Today? ↗

February 13, 2026

Healthcare stocks have lagged the market for years, but 2026 is looking much better.

Sector Alert: 4 Healthcare ETFs Poised for Explosive Growth Now ↗

February 11, 2026

Topics Artificial Intelligence ETFs Economy

5 Stocks and ETFs to Help Shield Your Portfolio During Volatility ↗

February 09, 2026

The acquisition will strengthen Lilly’s pipeline with a new class of therapies built on engineered circular RNA and proprietary lipid nanoparticles.

Topics ETFs

LLY Stock Climbs Pre-Market On $2.4 Deal To Acquire Orna Therapeutics ↗

February 09, 2026

Invesco KBW Bank ETF tracks a benchmark of major U.S. banking institutions, offering targeted sector exposure and a moderate yield.

Harel Insurance Sold $330 Million of Invesco KBW Bank ETF ↗

February 05, 2026

UNH Stock Craters To 6-Month Low: Piper Sandler Still Sees 40% Upside, Would Buy The Dip ↗

Topics ETFs Regulatory Compliance

January 28, 2026

UnitedHealth expects some membership contraction in 2026 and noted that CMS’s Medicare rate “simply doesn't reflect the reality.”

ALT Stock Surges Toward Sixth Straight Day Of Gains: Retail Bets A Buyout Is On The Horizon ↗

January 27, 2026

Altimmune plans to raise $75 million via a direct offering to bankroll its Phase 3 MASH trial, easing near-term funding risk.

According to a Calcalist report, the company is set to go private after a $1.1 billion acquisition by a fund.

INMD Stock Jumped Nearly 13% Today – What’s Powering The Rally? ↗

January 26, 2026

Revolution Medicines Stock Stares At Big Dip After Merck Reportedly Shelves Buyout — But Analyst Flags Opportunity ↗

Topics Artificial Intelligence

January 26, 2026

Stifel expects dip-buyers to step in, saying it would be surprised to see RVMD settle meaningfully below $100, calling the failed talks an “M&A clearing event.”